ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS
Boost For Lilly, Blow For Pfizer
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.
You may also be interested in...
Data from the PENELOPE-B study in high-risk early breast cancer patients show no separation from placebo, compounding the earlier failure of the PALLAS trial in low- and high-risk patients.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.